

**Question for written answer E-002272/2021  
to the Commission**

Rule 138

**Esther de Lange (PPE), Tom Berendsen (PPE)**

Subject: The production of medical isotopes in Europe

PALLAS is the new medical isotope reactor that will replace the outdated High Flux Reactor in Petten in The Netherlands. The aim of the Pallas project is to ensure security of supply of medical isotopes in Europe for the diagnosis and treatment of cancer in particular. The current High Flux Reactor in Petten meets around 70 % of European demand.

1. Is the Commission aware of the Pallas project to build a new research reactor in Petten to replace the outdated High Flux Reactor that can produce medical isotopes on a large scale for diagnostic and therapeutic purposes?
2. Does it agree that the Pallas project is contributing to the objectives of Europe's Beating Cancer Plan and the associated SAMIRA Action Plan, which seeks to bring about a 'European Radioisotope Valley Initiative' for strategic autonomy for the production of medical isotopes in Europe?
3. Given the confirmed benefits of and need for a new reactor for the production of medical isotopes in Europe, does the Commission intend to provide financial support for the Pallas project? If so, through which financing instruments?